Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma

Abstract Background Accumulation of malignant plasma cells in the bone marrow causes lytic bone lesions in 80% of multiple myeloma patients. Frequently fracturing, they are challenging to treat surgically. Myeloma cells surviving treatment in the presumably protective environment of bone lesions imp...

Full description

Saved in:
Bibliographic Details
Main Authors: Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Kim de Veirman, Thaqif El Khassawna, Christian Heiss, Anne Hild, Daniel Zahner, Francisca Alagboso, Anja Henss, Susanne Beck, Martina Emde-Rajaratnam, Jürgen Burhenne, Juliane Bamberger, Eline Menu, Elke de Bruyne, Michael Gelinsky, Marian Kampschulte, Marcus Rohnke, Sabine Wenisch, Karin Vanderkerken, Thomas Hanke, Anja Seckinger, Volker Alt
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Journal of Hematology & Oncology
Subjects:
Bone substitute material
Bortezomib
Multiple myeloma
Osteolytic bone lesions
Local treatment
Minimal residual disease
Online Access:https://doi.org/10.1186/s13045-024-01636-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items